Cognition Therapeutics, Inc. (CGTX) News
Follow Cognition Therapeutics, Inc. (CGTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
CGTX Reports Q3 Loss, Alzheimer’s Study Enrollment and Zervimesine Patent Update
EQUITY | Nov 06, 2026, 08:05 AM UTC
M
Cognition Therapeutics Reports Quarterly Results Through September 30
Cognition Therapeutics reported results for the quarter ended September 30. The supplied body contains no financial figures.
EQUITY | Nov 05, 2026, 01:39 PM UTC
M
Cognition Therapeutics Reports Q3 Net Loss
EQUITY | Nov 05, 2026, 11:20 AM UTC
M
Cognition Therapeutics Falls Below Nasdaq’s $1 Bid-Price Requirement
Nasdaq notified the company on November 3 that its closing bid price had remained below $1.00 for 30 consecutive business days. It has until May 3, 2027, to regain compliance; its shares continue to trade on Nasdaq Capit
REGULATION | Nov 05, 2026, 11:14 AM UTC
M
Cognition Therapeutics Reports Third-Quarter 2026 Financial Results
Cognition Therapeutics reported financial results for the third quarter of 2026.
EQUITY | Nov 05, 2026, 11:01 AM UTC
M
Cognition Therapeutics Schedules Q3 2026 Results Call for November 5
EQUITY | Nov 02, 2026, 12:30 PM UTC
L
Cognition Therapeutics receives composition-of-matter patent for zervimesine
The patent extends protection for zervimesine (CT1812) through 2045.
EQUITY | Oct 13, 2026, 10:00 AM UTC
L
Cognition Therapeutics, Inc. (CGTX) Sets FDA Type C Meeting to Align DLB Phase 3 Endpoint
Cognition Therapeutics scheduled an FDA Division of Neurology Type C meeting on Oct. 20, 2026 to align on the proposed primary endpoint for a planned registrational Phase 3 trial of zervimesine (CT1812) in DLB with psych
REGULATION | Sep 29, 2026, 11:33 AM UTC
L
CGTX - Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
CGTX - Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
EQUITY | Sep 08, 2026, 11:30 AM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Wednesday's intraday session, with Pulsenmore and Icecure Medical leading the gainers and Aditxt and Atlantic International among the losers
EQUITY | Jun 24, 2026, 05:05 PM UTC
H
CGTX: FDA Agrees On Outcome
Cognition Therapeutics reaches alignment with FDA on vital aspects to support its new drug application for psychosis associated with dementia with Lewy bodies
REGULATION | Jun 24, 2026, 11:42 AM UTC
M
CGTX Aligns Pivotal Study
Cognition Therapeutics aligns on key aspects of pivotal study for Zervimesine in DLB psychosis after receiving FDA meeting minutes
EARNINGS | Jun 24, 2026, 11:30 AM UTC